KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Cash & Equivalents (2016 - 2026)

Eli Lilly filings provide 18 years of Cash & Equivalents readings, the most recent being $5.3 billion for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 70.76% to $5.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $5.3 billion, a 70.76% increase, with the full-year FY2025 number at $7.3 billion, up 122.4% from a year prior.
  • Cash & Equivalents hit $5.3 billion in Q1 2026 for Eli Lilly, down from $7.3 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $9.8 billion in Q3 2025 to a low of $2.1 billion in Q4 2022.
  • Median Cash & Equivalents over the past 5 years was $3.1 billion (2025), compared with a mean of $3.7 billion.
  • Biggest five-year swings in Cash & Equivalents: tumbled 45.87% in 2022 and later soared 190.65% in 2025.
  • Eli Lilly's Cash & Equivalents stood at $2.1 billion in 2022, then skyrocketed by 36.36% to $2.8 billion in 2023, then grew by 15.94% to $3.3 billion in 2024, then surged by 122.4% to $7.3 billion in 2025, then fell by 27.33% to $5.3 billion in 2026.
  • The last three reported values for Cash & Equivalents were $5.3 billion (Q1 2026), $7.3 billion (Q4 2025), and $9.8 billion (Q3 2025) per Business Quant data.